Back to Browse Journals » Current Biomarker Findings » Volume 3

Immune biomarkers in irritable bowel syndrome: a review

Authors Gras-Miralles B, Kokkotou E

Published Date June 2013 Volume 2013:3 Pages 43—53

DOI http://dx.doi.org/10.2147/CBF.S29207

Received 24 October 2012, Accepted 3 April 2013, Published 17 June 2013

Beatriz Gras-Miralles, Efi Kokkotou

Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Abstract: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder that affects about 9%–13% of the general population. IBS is one of the main reasons to consult a primary care physician, and nearly 30% of visits to a gastroenterologist are for IBS. The diagnosis of IBS relies on subjective, patient-reported symptoms, thus making urgent the need for IBS-specific biomarkers. The same biomarkers, or perhaps different ones, can also be used to monitor disease evolution and response to treatment. A significant number of studies have looked in the immune system for establishing IBS biomarkers, based on the concept that IBS might represent a condition of immune dysregulation somewhere in the spectrum between health and inflammatory bowel disease. Such biomarkers can be detected in blood, intestinal biopsies, or luminal contents. Overall, results are rarely consistent between studies; small sample size, patient and disease heterogeneity, presence of comorbidities, and variation in sampling might contribute to these discrepancies. So far, studies have failed to provide a diagnostic immune biomarker for IBS, but they have considerably advanced our understanding of the disease pathophysiology, including the role of the individual's genetic make-up, and of the host–microbial interactions. High throughput analysis of a large number of well characterized patients holds promise for developing appropriate biomarkers for IBS.

Keywords: neuroimmune interactions, mast cells, genetic polymorphisms, cytokines, toll-like receptors

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Rhegmatogenous retinal detachment in children 16 years of age or younger

AL-Zaaidi S, AL-Rashaed S,AL-Kahtani E, AL-Harthi E, Abu El-Asrar A

Clinical Ophthalmology 2013, 7:1001-1014

Published Date: 17 June 2013

Serous endometrial intraepithelial carcinoma: a case series and literature review

Pathiraja P, Dhar S, Haldar K

Cancer Management and Research 2013, 5:117-122

Published Date: 17 June 2013

Two cases of male breast cancer at a university hospital in southeast Brazil

Rodrigues FR, da Silva AV, Teixeira CMLO, Antunes SCG, Rochael MC

International Journal of General Medicine 2013, 6:503-506

Published Date: 17 June 2013

Update on the challenges and recent advances in cancer immunotherapy

Baronzio G, Parmar G, Shubina IZH, Cassutti V, Giuli S, Ballerini M, Kiselevsky M

ImmunoTargets and Therapy 2013, 2:39-49

Published Date: 17 June 2013

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Rituximab and biosimilars – equivalence and reciprocity

Qureshi ZP, Magwood JS, Singh S, Bennett CL

Biosimilars 2013, 3:19-25

Published Date: 14 June 2013

Editorial

Khong HT

Current Biomarker Findings 2011, 1:1-2

Published Date: 1 April 2011